

Making Sure My Meds Are Safe
Manufacturers and Quality Controls

March 31, 2016

Brian Hasselbalch, Deputy Director (acting) Office of Policy for Pharmaceutical Quality Center for Drug Evaluation and Research FDA

**Site Inspections** 


**Surveillance Testing** 

Application/ License Review

Quality and Safety

**Feedback** 

Requirements



#### Requirements

- Regulations (e.g., CGMP)
- Pharmacopeia (e.g., <u>USP</u>)

**Surveillance Testing Site Inspections Feedback** Application/ **License Review** Quality and Safety

#### Requirements

- Regulations (e.g., CGMP)
- Pharmacopeia (e.g., USP)

- Guidance
- Outreach
- Partnerships

**Site Inspections** 

**Surveillance Testing** 

## Application/ License Review

- Pre-market review
- Annual reports

Quality and Safety

#### **Feedback**

#### Requirements

- Regulations (e.g., CGMP)
- Pharmacopeia (e.g., USP)

- Guidance
- Outreach
- Partnerships

## **Site Inspections**

- Pre-approval
- Surveillance
- Directed / "for-cause"

**Surveillance Testing** 

## Application/ License Review

- Pre-market review
- Annual reports

Quality and Safety

**Feedback** 

#### Requirements

- Regulations (e.g., CGMP)
- Pharmacopeia (e.g., USP)

- Guidance
- Outreach
- Partnerships

## **Site Inspections**

- Pre-approval
- Surveillance
- Directed / "for-cause"

## **Surveillance Testing**

- Finished product
- Active ingredients
- Inactive ingredients

## Application/ License Review

- Pre-market review
- Annual reports

Quality and Safety

**Feedback** 

## Requirements

- Regulations (e.g., CGMP)
- Pharmacopeia (e.g., USP)

- Guidance
- Outreach
- Partnerships

## **Site Inspections**

- Pre-approval
- Surveillance
- Directed / "for-cause"

## **Surveillance Testing**

- Finished product
- Active ingredients
- Inactive ingredients

## Application/ License Review

- Pre-market review
- Annual reports

# Quality and Safety

#### **Feedback**

- Defect reports
- Recalls
- Consumer complaints
- Trusted partner

#### Requirements

- Regulations (e.g., CGMP)
- Pharmacopeia (e.g., <u>USP</u>)

- Guidance
- Outreach
- Partnerships

## **Site Inspections**

- Pre-approval
- Surveillance
- Directed / "for-cause"

## **Surveillance Testing**

- Finished product
- Active ingredients
- Inactive ingredients

# Į

## Application/ License Review

- Pre-market review
- Annual reports

Quality and Safety

#### **Feedback**

- Defect reports
- Recalls
- Consumer complaints
- Trusted partner


## Regulatory Actions and Enforcement



# Periodically Inspected Manufacturing **Operations**

- Dosage form (e.g., tablets, capsules, creams, liquids, gas, transdermals, metered-dose inhalers)
- Active ingredient√
- Contract sterilizers
- Contract laboratories ✓
- Contract and independent packagers/labelers <
- Outsourcing facilities (i.e., "503B" compounders) ✓
- Drugs made in US only for export ✓
- Inspected for-cause:
  - Inactive ingredient and primary containers
  - Clinical trial material

# Integrated Quality Assessment Approach: IQA Team




A team of experts performing a quality assessment of an application—NDA, BLA, ANDA—based on risk and knowledge management



## Quality Regulations: Current Good Manufacturing Practice (CGMP) for Finished Pharmaceuticals

#### 21 CFR Part 211 subparts:

- General Provisions
- Organization and Personnel
- **Buildings and Facilities**
- Equipment
- Control of Components and Drug **Product Containers and Closures**
- Production and Process Controls
- Packaging and Labeling Control
- **Holding and Distribution**
- **Laboratory Controls**
- Records and Reports
- Returned and Salvaged Drug Products



# Office of Pharmaceutical Quality (OPQ)

Effective January 11, 2015

#### **Mission**

... ensures that **quality medicines are available** to the
American public

#### **Vision**

... be a **global benchmark** for regulation of pharmaceutical quality

## Slogan

"One Quality Voice"



www.fda.gov



www.fda.gov

CDER-OPQ-Inquiries@fda.hhs.gov